🌍 Global cancer drug news
💊 FDA, EMA & worldwide approvals
🔬 Breakthrough trials & new treatments
📊 Evidence, access & policy
Making sense of cancer care
🚨Cancer vaccines gain momentum in #Melanoma
After @moderna_tx mRNA-4157; Scancell reports Phase II iSCIB1+ DNA vaccine data
📊24-month OS 87%
✅PFS 71%
🎯CR 31%
Phase III Dec 2026 🇺🇸 FDA grants RMAT status
@jasonlukemd@MelanomaReAlli@jasonlukemd
https://t.co/5Vr947Flyf
🚨Positive Phase III trial in #GastricCancer
💊TroFuse015: sacituzumab tirumotecan (TROP2 ADC)
📊Significant OS benefit in 3L+ gastroesophageal cancer (n=473)
⚠️PFS not met but first TROP2 ADC with OS benefit
@KoheiShitara@YJanjigianMD@KlempnerSam
https://t.co/JuMySXDGEi
🚨Novel ADC at EORTC–NCI–AACR #ENA2026
Micvotabart pelidotin targets EDB-fibronectin in the tumour extracellular matrix
Phase I in R/M head &neck squamous cell carcinoma n=33
📊ORR 39%
📈Median PFS 6.7 months; Phase III planned
@PTarantinoMD@curijoey
https://t.co/F3eIwiSLrW
🚨EU approves #daraxonrasib for metastatic pancreatic cancer!
📊 Median OS: 12.4 vs 6.7 months with chemotherapy.
🇺🇸 USA: Approved
🇪🇺 EU: Approved
🇬🇧 UK: Not yet
🇨🇭 Switzerland: Not yet
🇨🇦 Canada: Not yet
🇯🇵 Japan: Not yet
When will patients worldwide get access?
@OncoAlert
The European Commission has granted marketing authorization for our oral RAS(ON) multi-selective inhibitor for previously treated metastatic pancreatic cancer.
Read more: https://t.co/QLZ5HmQyFK
#ForMediaOnly
🚨 Major FDA setback for Ivonescimab!
FDA issues a Complete Response Letter for ivonescimab + chemotherapy in EGFR-mutated NSCLC following the Phase III HARMONi trial.
✅ Significant PFS benefit
❌ OS benefit not statistically significant
📊 Post-hoc OS HR: 0.76
FDA's message: PFS benefit alone was insufficient to establish a favorable benefit–risk profile in this setting.
A major regulatory challenge for the promising PD-1/VEGF bispecific antibody
Is PFS enough, or should OS remain the ultimate benchmark? @JacobPlieth@RManochakian@OncoAlert@OncBrothers@dr_yakupergun@KolPulseAI
For patients with resectable locally advanced #HeadAndNeckSquamousCellCarcinoma, perioperative camrelizumab plus chemotherapy improved 2-year event-free survival vs standard surgery-based treatment. https://t.co/CFfn5W1NJh
🚨New peak AI in academic publishing?
This paper contains a extraordinary instruction in its Data Availability Statement:
An attempt to get AI reviewers to recommend acceptance? 😂
@pash22@MicrobiomDigest@ivanoransky@gcabanac@Richvn@nickwizzo
🔗 https://t.co/L9OncCYHWY